Humana Stock Price Target Raised by Analysts, $214.00 and $250.00

Multiple analysts have announced price target increases for Humana's (NYSE:HUM) stock price. JPMorgan's price target was raised to $214.00 [doc1 & doc4]. This was reinforced by a separate announcement that also stated a price target of $214 by JP Morgan. TD Cowen also raised their price target to $211. Meanwhile, Cantor Fitzgerald and Leerink Partners analysts have expressed expectations for a stock price rise [doc7 & doc8]. Additionally, a different analyst raised their price target to $250.00.

The upgrades follow an extended period of pressure on managed care stocks driven by higher-than-expected Medicare Advantage utilization rates in 2024–2025. Analysts raising targets now appear to be signaling that the utilization cycle has peaked and that HUM's earnings trajectory is recovering — with the company having reset its cost structure through 2025 restructuring initiatives that reduced headcount and renegotiated provider contracts.

Health insurers face a complex backdrop: Medicare Advantage rates are set annually by CMS, adding a regulatory layer that limits pricing flexibility, while the political environment around drug pricing and insurer margins remains contentious. However, Humana's near-total concentration in Medicare Advantage — roughly 90% of revenue — means it is a direct beneficiary if enrollment growth reaccelerates in 2026 as the demographic tailwind from aging Baby Boomers strengthens.

Related Stocks

• HUM